title: Reversible pre-capillary pulmonary hypertension due to dasatinib.
abstract: Pulmonary arterial hypertension and secondary pleural effusion have been reported in association with long-term therapy with the multi-tyrosine kinase inhibitor dasatinib, approved for the treatment of chronic myeloid leukemia. Here, we present the case of a 50-year-old man, diagnosed with chronic myeloid leukemia in August 2003, who developed pulmonary arterial hypertension after > 4 years of treatment with dasatinib. The complete remission of pulmonary arterial hypertension following dasatinib discontinuation suggests an etiological role of the drug in its development, although the administration of sildenafil may have played a therapeutic role.
authors.affiliation: Pneumology Department.
authors.forename: Herminia L
authors.initials: HL
authors.lastname: Buchelli Ramirez
authors.forename: Celso M
authors.initials: CM
authors.lastname: Álvarez Álvarez
authors.forename: José J
authors.initials: JJ
authors.lastname: Rodríguez Reguero
authors.forename: Marta M
authors.initials: MM
authors.lastname: García Clemente
authors.forename: Pere
authors.initials: P
authors.lastname: Casan Clarà
mesh_terms: D000069439:Dasatinib; D006801:Humans; D006976:Hypertension, Pulmonary / Q000139:chemically induced* / Q000188:drug therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011687:Purines / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects*; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000627:therapeutic use; D013844:Thiazoles / Q000009:adverse effects*
chemical_list: D058986:Phosphodiesterase 5 Inhibitors; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011687:Purines; D011743:Pyrimidines; D013450:Sulfones; D013844:Thiazoles; D000068677:Sildenafil Citrate; D000069439:Dasatinib
keywords: chronic myeloid leukemia; drug-induced; long-term therapy; pulmonary hypertension